EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Protocol for EVOLVE-HBV, a study to determine the prevalence and characteristics of chronic hepatitis B virus infection in KwaZulu-Natal, South Africa, to inform interventions for diagnosis, treatment and prevention

Motswedi Anderson iD, Tongai G Maponga iD, Janine Upton iD, Gloria Sukali iD, Lusanda Mazibuko iD, Kathy Baisley iD, Theresa Smit iD, Elizabeth Waddilove iD, Marion Delphin iD, Dickman Gareta iD, Nikiwe Mbatha, Landiwe Ndimande iD und 27 weitere

Sage Open Chronic Disease · 2026-02 · 17

DOI: 10.1177/27558428261459232 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Sage Open Chronic Disease, online erschienen am 14.08.2026. Verfasst von Motswedi Anderson und 38 weiteren Autor:innen. Beteiligte Einrichtung: Africa Health Research Institute, KwaZulu-Natal, South Africa. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Africa Health Research Institute Research Awards, Francis Crick Institute, university college london.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis B virus (HBV) infection is endemic in many African populations, but has been neglected by funding, education, clinical infrastructure and research. High-profile international targets have been set for HBV elimination by 2030.

Objectives

We here present the protocol for EVOLVE-HBV, an interdisciplinary study based at the Africa Health Research Institute aiming to quantify and characterize HBV infection in the KwaZulu-Natal (KZN) province, South Africa. The study aims to develop insights into HBV by assessing population knowledge, epidemiology, clinical features and laboratory characteristics, with the overall aim of enhancing local care pathways.

Design

Study phase I is a retrospective, observational cross-sectional assessment of HBV sero-epidemiology. Phase II incorporates the prospective recruitment of adults living with HBV and HBV-negative controls from the same community. Study dates are 1 August 2023 to 31 July 2027.

Methods

The study is supported by an active programme of community engagement. Phase I: banked samples are tested for HBV serum markers in a clinical diagnostic laboratory and analysed to generate weighted estimates of HBV infection, exposure and immunity. Phase II: data are collected through questionnaire, clinical assessment, biometric data, imaging using Fibroscan™ and laboratory assays including measurement of biomarkers, antiviral drug concentrations and HBV whole genome sequencing. Social scientists collect qualitative data regarding beliefs, experiences and needs of the community. Data across all themes inform a detailed picture of the sociodemographic, clinical and molecular characteristics of HBV infection. Ethics: EVOLVE-HBV is approved by the University of KZN Biomedical Research Ethics Committee in South Africa (ref. 00004495/2022), and University College London (UCL) ethics committee in the United Kingdom (ref. 23221/001).

Discussion

This protocol describes a study that will inform insights into local HBV epidemiology, determine the need for scale-up of vaccination, screening and treatment, inform local policy, education and service-development and provide an evidence-based foundation for future clinical practice and translational research. Collectively, this work aims to inform improvements in clinical and public health strategies to support progress towards 2030 targets.

Schlagwörter

Stichwörter der Autor:innen

HBVSouth Africacommunity engagementeliminationepidemiologyexposurehepatitis Bimplementationinfectionmental healthprevalenceprotocolserologyvaccine

Autor:innen und Institutionen

  • Africa Health Research Institute, KwaZulu-Natal, South Africa.
  • Botswana Harvard Health Partnership Institute, Gaborone, Botswana.
  • The Francis Crick Institute, London, UK.
  • Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • National Health Laboratory Service, Tygerberg Business Unit, Cape Town, South Africa.
  • Division of Infection and Immunity, University College London, London, UK.

ORCID-Profile: Motswedi Anderson, Tongai G Maponga, Janine Upton, Gloria Sukali, Lusanda Mazibuko, Kathy Baisley, Theresa Smit, Elizabeth Waddilove, Marion Delphin, Dickman Gareta, Landiwe Ndimande, Njabulo Dayi, Gregory Ording-Jespersen, Ngcebo Mhlongo, Guy Harling, Alasdair Leslie, Xanthe Hunt, Nokukhanya Msomi, Resign Gunda, Vasudevan G Naidoo, Mark Siedner, Emily B Wong, Janet Seeley, Thandeka Khoza, Collins Iwuji, Philippa C Matthews

Förderung

  • Africa Health Research Institute Research Awards
  • Francis Crick Institute
  • university college london
  • Africa Health Research Institute-University College London PhD Scheme
  • royal society
  • Africa Oxford Initiative ‘AfOx’ Research Development Award
  • university college london hospitals biomedical research centre
  • Wellcome Trust

Zitieren

APA

Anderson, M., Maponga, T. G., Upton, J., Sukali, G., Mazibuko, L., Baisley, K., Smit, T., Waddilove, E., Delphin, M., Gareta, D., Mbatha, N., Ndimande, L., Dayi, N., Ording-Jespersen, G., Myeni, N., Ngwenya, B., Mpanza, N., Govender, K., Mhlongo, N., …, & Matthews, P. C. (2026). Protocol for EVOLVE-HBV, a study to determine the prevalence and characteristics of chronic hepatitis B virus infection in KwaZulu-Natal, South Africa, to inform interventions for diagnosis, treatment and prevention. Sage Open Chronic Disease, 17. https://doi.org/10.1177/27558428261459232

Vancouver

Anderson M, Maponga TG, Upton J, Sukali G, Mazibuko L, Baisley K, et al. Protocol for EVOLVE-HBV, a study to determine the prevalence and characteristics of chronic hepatitis B virus infection in KwaZulu-Natal, South Africa, to inform interventions for diagnosis, treatment and prevention. Sage Open Chronic Disease. 2026;17. doi:10.1177/27558428261459232

BibTeX
@article{Anderson2026,
  author = {Anderson, Motswedi and Maponga, Tongai G and Upton, Janine and Sukali, Gloria and Mazibuko, Lusanda and Baisley, Kathy and Smit, Theresa and Waddilove, Elizabeth and Delphin, Marion and Gareta, Dickman and Mbatha, Nikiwe and Ndimande, Landiwe and Dayi, Njabulo and Ording-Jespersen, Gregory and Myeni, Njabulo and Ngwenya, Busangani and Mpanza, Nondumiso and Govender, Katya and Mhlongo, Ngcebo and Harling, Guy and Leslie, Alasdair and Majozi, Nomathamsanqa and Siwela, Dumisani and Hunt, Xanthe and Ndlovu, Bongiwe and Mthethwa, Lulama and Msomi, Nokukhanya and Ansari, M Azim and Gunda, Resign and Naidoo, Vasudevan G and Temmers, Shaun R G and Ndung'u, Thumbi and Shahmanesh, Maryam and Siedner, Mark and Wong, Emily B and Seeley, Janet and Khoza, Thandeka and Iwuji, Collins and Matthews, Philippa C},
  title = {Protocol for EVOLVE-HBV, a study to determine the prevalence and characteristics of chronic hepatitis B virus infection in KwaZulu-Natal, South Africa, to inform interventions for diagnosis, treatment and prevention},
  journal = {Sage Open Chronic Disease},
  year = {2026},
  volume = {17},
  doi = {10.1177/27558428261459232}
}
Kostenlos starten →